Journal Mobile Options
Table of Contents
Vol. 12, No. 1, 2001
Issue release date: January–February 2001
Dement Geriatr Cogn Disord 2001;12:40–51

Neuritogenic-Neurotoxic Effects of Membrane-Associated Forms ofAmyloid Precursor Prot ein

Neill D. · Hughes D. · Leake A. · Morris C. · Jones D. · Oakley A. · Edwardson J. · Estibeiro P.
aInstitute for the Health of the Elderly, Newcastle General Hospital, Newcastle upon Tyne, bSouth Tyneside District Hospital, South Shields, cCentre for Genome Research, University of Edinburgh, Edinburgh, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The membrane-bound glycoprotein, amyloid precursor protein (APP), plays a central role in Alzheimer’s disease (AD). The present paper investigates the neuritogenic-neurotoxic properties of this protein and relates them to possible aetiopathological mechanisms in AD. Marked differences in neuritic differentiation were detected when comparing untransfected tetraploid mouse neuroblastoma cells (or vector only cells) with transfected cells overexpressing APP751. Transfected cells developed neurites quicker, and whereas all transfected cells differentiated, the degree of differentiation of untransfected cells was more variable. Fully differentiated transfected and untransfected cells had marked differences in neuritic morphology. Transfected cells had more neurites per cell, these being shorter and more branched than neurites on untransfected cells. The precocious differentiation of transfected cells was not maintained with neuritic process disintegration and cell death occurring from the seventh day onwards. Untransfected cells continued to extend their neuritic processes for up to five weeks. Membrane-associated forms of APP were responsible for these effects, rather than secreted APP or the β/A4-peptide. Combined data from Western blot and immunocytochemical procedures showed a prominent accumulation of APP-C-terminal fragments in the perinuclear region, neuritic varicosities and growth cones of transfected cells, suggesting their involvement in the neuritogenic-neurotoxic process. Similar neuritogenic-neurotoxic mechanisms occurring in vivo, in association with compensatory synaptoplastic responses in the aged brain, may be part of the pathological process in AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Glenner GG, Wong CW: Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885–890.
  2. Masters CL, Simms G, Weinmann NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque protein in Alzheimer’s disease and Down’s syndrome. Proc Natl Acad Sci USA 1985;82:4245–4249.
  3. Kidd M: Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature 1963;197:192–193.
  4. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LT: Abnormal phosphorylation of the microtubule associated protein tau in Alzheimer’s cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913–4917.
  5. Ihara Y, Nukina N, Miura R, Ogawara M: Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer’s disease. J Biochem 1986;99:1807–1810.

    External Resources

  6. Kang J, Lemaire HG, Unterbek A, Salbaum JM, Masters CL, Crzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B: The precursor of Alzheimer’s disease amyloid beta protein resembles a cell surface receptor. Nature 1987;325:733–736.
  7. Kitaguchi N, Takahashi Y, Tokushima Y, Shojiri S, Ito H: Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity. Nature 1988;331:530–532.
  8. Ponte P, Gonzalez-DeWhitt P, Schilling J, Miller J, Hsu D, Greenberg B, Davis K, Wallace W, Lieberburg I, Fuller F, Cordell B: A new β amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 1988;331:525–527.
  9. Allsop D, Kennedy HE, Kametani F: Secretory derivatives of Alzheimer’s amyloid precursor protein in cerebrospinal fluid and brain: Only Kunitz-containing forms show amyloid immunoreactivity; in Corain B, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta P (eds): Alzheimer’s Disease: Advances in Clinical and Basic Research. Chichester, Wiley, 1993, pp 421–429.
  10. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ: Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322–325.
  11. Palmert MR, Podlinsky MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG: The β-amyloid protein precursor of Alzheimer’s disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci USA 1989;86:6338–6342.
  12. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai X-D, McKay DM, Tinter R, Frangione B, Younkin SG: Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992;258:126–129.
  13. Weideman A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters C, Beyreuther K: Identification, biogenesis and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell 1989;57:115–126.
  14. Hardy J: Framing β-amyloid. Nat Genet 1992;1:233–234.

    External Resources

  15. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol 1991;12:383–388.
  16. Neill D: Alzheimer’s disease: ‘Maladaptive Synaptoplasticity Hypothesis’. Neurodegeneration 1995;4:217–232.
  17. Moya KL, Benowitz LI, Schneider GE, Allinquants B: The amyloid precursor protein is developmentally regulated and correlates with synaptogenesis. Dev Biol 1994;161:597–603.

    External Resources

  18. Schubert W, Prior R, Weideman A, Dircksen H, Multhaup G, Masters CL, Beyreuther K: Localization of Alzheimer β/A4 amyloid precursor protein at central and peripheral synaptic sites. Brain Res 1991;563:184–194.
  19. Neve LN, Finch EA, Bird ED, Benowitz L: Growth-associated protein GAP-43 is expressed selectively in associative regions of the adult human brain. Proc Natl Acad Sci USA 1988;85:3638–3642.
  20. Benowitz LI, Perrone-Bizzozero NI: The relationship of GAP43 to the development and plasticity of synaptic connections. Ann NY Acad Sci 1991;627:58–74.

    External Resources

  21. Masliah E, Mallory M, Hansen L, Alford M, DeTeresa R, Terry R, Baudier J, Saitoh T: Localization of amyloid precursor protein in GAP43-immunoreactive aberrant sprouting neurites in Alzheimer’s disease. Brain Res 1992;574:312–316.
  22. Jin L-W, Ninomiya H, Roch J-M, Schubert D, Masliah E, Otero DAC, Saitoh T: Peptides containing the RERMS sequences of amyloid β/A4 protein precursor bind cell surface and promote neurite extension. J Neurosci 1994;14:5461–5470.

    External Resources

  23. Qiu QW, Ferreira A, Miller C, Koo EH, Selkoe DJ: Cell-surface β-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J Neurosci 1995;15:2157–2167.
  24. Koo EH, Park L, Selkoe DJ: Amyloid β-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci USA 1993;90:4748–4752.
  25. Ishii T, Kametani F, Haga S, Sato M: The immunohistochemical demonstration of sub-sequences of the precursor of the amyloid A4-protein in senile plaques in Alzheimer’s disease. Neuropathol Appl Neurobiol 1989;15:135–147.

    External Resources

  26. Estus S, Golde TE, Kunishita T, Blades D, Lowery D, Eisen M, Usiak M, Qu X, Tabira T, Greenberg BD, Younkin SG: Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science 1992;255:726–728.

    External Resources

  27. Schagger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 1987;166:368–379.
  28. Wasco W, Gurubhagavatula S, Paradis M, Rommano DM, Sisodia SS, Hyman BT, Neve RL, Tanzi RE: Isolation and characterisation of APLP2 encoding a homologue of the Alzheimer associated amyloid β protein precursor. Nat Genet 1993;5:95–100.
  29. Caceres A, Banker G, Steward O, Binder L, Payne M: MAP2 is localized to the dendrites of hippocampal neurons which develop in culture. Brain Res Dev Brain Res 1984;13:314–318.

    External Resources

  30. Friedrich P, Aszodi A: MAP2: A sensitive cross-linker and adjustable spacer in dendritic architecture. FEBS Lett 1991;295:5–9.
  31. Hollenbeck PJ: The transport and assembly of the axonal cytoskeleton. J Cell Biol 1989;108:223–227.
  32. Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kimura J: Trophic effect of β-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun 1991;181:265–271.

    External Resources

  33. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL: The amyloid precursor protein of Alzheimer’s disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 1992;9:129–137.
  34. Maruyama K, Kumagae Y, Saito Y, Yamao-Harigaya W, Usami M, Ishiura S, Kawashima S, Obata K: The toxic effect of Alzheimer amyloid precursor overexpressed in the neuroblastoma cell line NB-1 on neurite outgrowth. Gerontology 1994;40(suppl 2):57–64.
  35. Bahr BA, Hoffman KB, Yang AJ, Hess US, Glabe CG, Lynch G: Amyloid β protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol 1998;397:139–147.
  36. Yoshikawa K, Aizawa T, Hayshi Y: Degeneration in vitro of post-mitotic neurons overexpressing the Alzheimer amyloid protein precursor. Nature 1992;359:64–67.
  37. McPhie DL, Lee RKK, Eckman CB, Olstein DH, Durham SP, Yager D, Younkin SG, Wurtman RJ, Neve RL: Neuronal expression of β-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid β and cytoplasmic domains. J Biol Chem 1997;272:24743–24746.
  38. Sato M, Kawarabayashi T, Shoji M, Kobayashi T, Tada N, Matsubara E, Hirai S: Neurodegeneration and gliosis in transgenic mice overexpressing a carboxy-terminal fragment of Alzheimer amyloid-β protein precursor. Dement Geriatr Cogn Disord 1997;8:296–307.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50